Pascal Prigent, Genfit CEO
Ipsen fronts $136M to bag Genfit's once-failed NASH drug, betting on its potential in rare liver condition
Somebody believes in elafibranor after all.
The drug, which had been considered a bright prospect in the failure-prone but highly lucrative race to treat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
